The present study aims to investigate whether the dosage of the GnRH agonist used for triggering final oocyte maturation affects the maturity of the oocytes retrieved in high risk for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and recombinant FSH.
Three different doses of GnRH agonist (0.1mg, 0.2mg or 0.4 mg) will be used randomly to trigger final oocyte maturation. The primary outcome measure will be the percentage of mature oocytes retrieved. Secondary outcomes will include: number of oocytes retrieved, oocyte recovery rate (number of oocytes retrieved/ number of follicles \>11mm in diameter on the day of triggering), fertilization rates and OHSS occurrence. Serum LH, FSH, E2, PRG levels will be assessed at 8-36 hours following agonist administration and on days 3-4-7-10 after triggering final oocyte maturation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
90
Eugonia IVF Unit
Athens, Greece
RECRUITINGUnit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Thessaloniki, Greece
RECRUITINGPercentage of mature oocytes retrieved
Percentage of mature oocytes retrieved following oocyte retrieval
Time frame: 36 hours post GnRH agonst administration
total number of oocytes retrieved
Time frame: 36 hours post GnRH agonist administration
oocyte recovery rate
Time frame: 36 hours post GnRH agonist administration
Fertilization rate
Time frame: Day 1 post oocyte retrieval
Serum LH, FSH, E2, PRG levels
Time frame: 8-36 hours post triggering and on days 3-4-7-10 after GnRH agonist administration
Duration of luteal phase
Time frame: 16 days
OHSS occurrence
Occurrence of ovarian hyperstimulation syndrome
Time frame: 16 days post triggering
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.